THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but stock risks remain. See more on JANX.

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

News Daybreak has the headlines you need to know to get your Friday started. The Nebraska State Patrol shared more examples ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

It’s that time of year again! The North Country Festival of Trees is right around the corner. K.I. LaClair and Dawn Atwood ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment ...

Background Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...

The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.